AI is no stranger to the medical field, but VUNO - the first AI medical device company in Korea - has set a record in pushing beyond the boundaries of basic AI medical imaging solutions into the field of diagnostic pathology.  

 

VUNO has expedited preparations for clinical trials with the aim of obtaining approval by early next year for its gastric cancer pathology AI solution 'VUNO Med-PathGC AI™', which was jointly researched and developed with GC Labs.

 

The Korean national health checkup numbers indicate that early gastric cancer screenings had surged (number of gastric cancer examinees increased from 3.30 million to 4.19 million from 2011 to 2019), but there is still concern over the low 60.7% who actually get to see a pathologist for a biopsy. In this regard, Vuno Med Path-GC AI™ proved its excellent efficacy and accuracy in diagnosis, raising hopes for future diagnoses.



 

According to the official paper published in Clinical Cancer Research (IF=10.107) by the American Association for Cancer Research, which is one of the three largest cancer societies in the world, VUNO Med-PathGC AI™ showed a high accuracy of 100% sensitivity and 97% specificity in a prospective study for detection of gastric cancer and gastric adenoma, which are epithelial tumors.

 

Additionally, VUNO Med-PathGC AI™ demonstrated high efficiency in comparison to the digital pathology system group equipped with the traditional microscope and viewer, as the diagnosis time was reduced by up to 58% based on the same accuracy (AUROC standard). 

 

The Vice President of GC Labs, Kim Dong-il, who participated in the development of the VUNO Med-PathGC AI™, said, “Since the types of gastric cancer are so diverse, the diagnosis of gastric biopsy is difficult, and misdiagnosis may occur due to decreased concentration from overworking. However, this high-performance VUNO Med-PathGC AI™ solution can dramatically improve the accuracy of the biopsy results.” He then added that “if the solution is commercialized, it can successfully enter overseas markets as an essential tool across Asia for the diagnosis of gastric cancer.”

 

Beyond gastric cancer, VUNO plans to further strengthen its position as a leading company in pathology AI solutions by expanding its research into additional fields, such as lymph nodes and prostate cancer diagnostic models.

 

Since 2018 with the support of the Korea International Cooperation Agency, VUNO has also been developing VUNO Med®-TriVu™, a pathology-based AI solution for diagnosing sexually transmitted diseases. It has already demonstrated global prominence in the AI pathology field, with Mongolia adopting the system as the national standard inspection method through an innovative technology program Seed2, and VUNO continues to spur overseas expansion in its effort towards digital pathology innovation.


 



South Korean artificial intelligence (AI) developer VUNO Inc. joined the first batch of innovative medical device companies certified by the Ministry of Health and Welfare (MOHW) on Dec. 1, being categorized as an innovative takeoff-type business.

 

As the soaring exports of South Korean COVID-19 test kits led to a growing interest in the medical device industry, the MOHW launched a project to pick out a group of innovative medical device companies which have the potential to lead the medical device industry based on technological innovative capability, industry-specific specialty and expertise. The top 30 companies were selected by the ministry among a total of 102 applicants, highly acknowledged for their competence in medical device research & development and global competitiveness.

 

Widely renowned as a pioneering startup for its unprecedented success in making deep learning available on the South Korean medical IT industry, VUNO wrote a new chapter of its history by rolling out the nation's first medical AI solution VUNO Med®-BoneAge™ in 2018. VUNO enables comprehensive data analysis, including medical imaging including X-ray, CT, MRI, and fundus images, biosignal, pathology images and speech, and uses its extensive experience in multi-modal analyses & technologies, Putting work efficiency and accuracy in clinical medicine first and foremost, VUNO is always enthusiastic about developing and putting various medical AI software programs to clinical use. It has been graining great traction at home and abroad with more than 200 active users of hospitals and is ready to deploy the CE marked products to international business partners and clients across different markets.

 

In July, VUNO Med®-Fundus AI™ set a remarkable milestone by becoming the first innovative medical device in South Korea. It analyzes retinal fundus images to detect 12 abnormal lesions and classifies them for diagnosis. The 12 findings detected by the device are an all–encompassing set of medical information that is crucial to diagnosing a wide range of retinal diseases including diabetic retinopathy, macular degeneration and glaucoma.

 

Furthermore, Med®-DeepCARS™ also designated as an innovative medical device. It is the first bio-signal-based AI medical device to receive a regulatory green light from the Ministry of Food and Drug Safety (MFDS) on conducting clinical trials. The software predicts the risk of cardiac arrest occurring within the next 24 hours by doing an analysis of vital signs including pulse, respiratory rate, blood pressure and body temperature.



Medical artificial intelligence (AI) solution development company VUNO Inc. announced that it ranked first in the Retinal Fundus Glaucoma Challenge Edition (REFUGE2).

 

REFUGE2 was organized in conjunction with the 8th workshop of MICCAI(the Medical Image Computing and Computer Assisted Intervention Society) – one of the world's most prestigious associations for medical image processing – for three months from July 2020. A total of 134 teams across all over the world joined the REFUGE2 to claim the title of owning the best-performing deep learning algorithm to automatically detect glaucoma based on fundus image data. 

 

VUNO proudly became the final winner of the REFUGE2 this year by outperforming all other competitors in its three research challenges: Classification of Clinical Glaucoma; Segmentation of Optic Disc and Cup; and Localization of Fovea (macular center). VUNO proved its world-class level of technological prowess in AI-based glaucoma detection, one of the most fiercely competitive fields where world-famous businesses scramble to make their technology available on the market.

 

The winning of the REFUGE2 is only the latest in a long line of the remarkable achievements that VUNO has so far made in various international competitions. VUNO boasted its outstanding technological competence in the Automatic Detection Challenge on Age-related Macular degeneration (ADAM) and the DeepDR Diabetic Retinopathy Image Dataset (DeepDRiD), two of which were part of the International Symposium on Biomedical Imaging (ISBI) 2020. Back in 2018, the South Korean AI-based solution developer also garnered the honor of topping the Diabetic Retinopathy – Segmentation and Grading Challenge in the ISBI 2018 and the REFUGE in the MICCAI 2018.

 

"It is my great pleasure to see that VUNO earned praise for its outstanding technological excellence in AI-based fundus image analysis and glaucoma detection in this year's REFUGE,” said Jaemin Son, leader of eye imaging research team of VUNO. "I seek to make a continued effort to lead research and development so that not only the domestic market but also the rest of the globe can highly acclaim VUNO Med®-Fundus AI™, the innovator's fundus screening solution which perfectly embodies its technological expertise,” he added.

 

VUNO Med®-Fundus AI™, VUNO’s AI based screening solution for the fundus, analyzes retinal fundus images to validate and detect more than 12 lesions and provides diagnosis within one second. The 12 findings detected by the device: ▲hemorrhage, ▲hard exudate, ▲cotton wool patch, ▲drusen, ▲membrane, ▲macular hole, ▲myelinated nerve fiber, ▲chorioretinal atrophy or scar, ▲vascular abnormality, ▲retinal nerve fiber layer defect, ▲glaucomatous disc change, and ▲non-glaucomatous disc change, encompass all findings that are essential in diagnosing all retinal diseases including diabetic retinopathy, macular degeneration, and glaucoma.



VUNO, a member company of the Born2Global Centre, announced that their AI based screening solution for the fundus, VUNO Med®-Fundus AI™ is approved as a Class III medical device by the Ministry of Food and Drug Safety. VUNO Med®-Fundus AI™ is the first ever AI device to gain a Class III approval in Korea and is clinically validated to provide highly accurate screening results.

 

According to the research paper published in Ophthalmology, one of the most prestigious journals in the field, the solution's clinical validation (AUROC) of the 12 findings resulted in in impressive range of 96.2 to 99.9%, and 94.7 to 98.0% with external datasets, proving its stable performance and meaningful accuracy.

 

VUNO recently ranked first place at the ISBI 2020 fundus images challenge, one of three most prominent international biomedical imaging competitions, gaining international recognition for its outstanding technology. VUNO demonstrated outstanding performance in 3 out of 4 task categories, firmly securing its place as the best player in the field following the winning of the same competition in 2018.

 

 

Provides all findings that are essential in diagnosing all retinal diseases, it will be a key ophthalmological solution

 

AI based VUNO Med®-Fundus AI™ analyzes retinal fundus images to detect and locate more than 12 lesions within one second. The 12 findings detected by the device: hemorrhage, hard exudate, cotton wool patch, drusen, membrane, macular hole, myelinated nerve fiber, chorioretinal atrophy or scar, vascular abnormality, retinal nerve fiber layer defect, glaucomatous disc change, and non-glaucomatous disc change, encompass all findings that are essential in diagnosing all retinal diseases including diabetic retinopathy, macular degeneration, and glaucoma.

 

The fundus examination is carried out to observe the state of the fundus, made up of the retina, optic nerve, and retinal blood vessels that play key roles in eyesight. This procedure is known to offer early detections of diabetic retinopathy, macular degeneration, and glaucoma--three main diseases that may lead to loss of sight.

 

VUNO Med®-Fundus AI™ was developed based on a large-scale deep learning dataset of more than 100,000 fundus images that have been examined by more than 50 ophthalmologists including 28 specialists. The training dataset was collected from various retinal cameras (CF60Uvi, CR6-45NM, VX-10, VX-10a, nonmyd 7, and GENSIS-D).

 

 

Stable performance matching that of retina specialists was verified on an external validation exam incorporating multi-ethnic, multi-center settings.

 

For more detailed information on VUNO, visit https://www.vuno.co/.

 

 

 In the face of the COVID-19 pandemic raging around the globe, VUNO, a member company of the Born2Global Centre, has decided to move quickly by joining the global coalition to help address some critical issues facing the international healthcare community today by putting AI into work. VUNO, as the leading AI medical imaging software company, has been inundated with requests over the last several weeks regarding how they can help doctors remain resilient and better respond to the spread of the infection and ultimately contribute to saving lives doing what they can do well.

 

 

In an effort to help the medical community, VUNO accelerated the development and enhancement of their exiting AI algorithms to better meet the specific needs and demands from exhausted doctors who willingly put themselves at risk to save lives in the fight against COVID-19.

 

With that mission in mind, VUNO is now offering a suite of AI solutions VUNO Med®- LungQuant™ and VUNO Med®-Chest X-ray™: COVID-19, encompassing both lung X-ray and CT modalities respectively all at once. VUNO's one-stop service offering will allow users to choose one or both algorithms to use depending on their own needs by simply visiting one website without the hassle of moving from different AI systems.

 

The special versions of two AI products are released this week. These are web-based services available at https://covid19.vunomed.com/ for free for anyone who wants to use VUNO's AI algorithms to analyze a chest X-ray or CT scan.



 

What VUNO Solutions Offer

 

The common theme of the two AI solutions is to empower healthcare providers to provide better patient care by assisting them in the screening, diagnosis, and management of COVID-19 infected patients using our AI technology. They are developed to help protect healthcare providers from burnout or help overworked doctors on the edge of exhaustion in virus fight make a speedier and more accurate diagnostic decision in a difficult time like now. In addition, VUNO's cloud-based service offering will enable remote result reading and tracking of the status of patients infected with COVID-19, where radiologists are not readily available.  



http://www.venturesquare.net/world/lunit-insight/

 

 

Link from 

 

 

Our member in this article

 

Description

Learn What We Contribute to Medicine

        

 

 

 

http://www.koreaherald.com/view.php?ud=20170507000273

 

 

 

Link from 


 

Our member in this article

 

Description

VUNO is solving many different medical issues based on both VunoNet, a self-developed deep learning engine and VunoMed, 

a medical data analysis platform.

 

 

 

 

 

 

 

http://www.koreaherald.com/view.php?ud=20170507000273

 

 

 

Link from 


 

Our member in this article

 

Description

VUNO is solving many different medical issues based on both VunoNet, a self-developed deep learning engine and VunoMed, 

a medical data analysis platform.

 

 

 

 

 

 

 

http://www.koreaherald.com/view.php?ud=20170507000273

 

 

 

Link from 


 

Our member in this article

 

Description

VUNO is solving many different medical issues based on both VunoNet, a self-developed deep learning engine and VunoMed, 

a medical data analysis platform.

 

 

 

 

 

 

 

http://www.koreaherald.com/view.php?ud=20170507000273

 

 

 

 

Link From 

 

Our member in this article

 

 

Description

VUNO is solving many different medical issues based on both VunoNet, 

a self-developed deep learning engine and VunoMed, 

a medical data analysis platform.


 

 

 

Newsletter Sign Up

By clicking "submit," you agree to receive emails from Bron2Global and accept our web terms of use and privacy and cookie policy*Terms apply.